ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
Identifieur interne : 000943 ( Main/Corpus ); précédent : 000942; suivant : 000944ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
Auteurs : K L Winthrop ; X. Mariette ; J T Silva ; E. Benamu ; L H Calabrese ; A. Dumusc ; J S Smolen ; J M Aguado ; M. Fernández-RuizSource :
- Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [ 1469-0691 ] ; 2018.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal (adverse effects), Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (therapeutic use), Biological Therapy (adverse effects), Clinical Trials as Topic (MeSH), Communicable Disease Control (MeSH), Communicable Diseases (immunology), Communicable Diseases (therapy), Complement System Proteins (drug effects), Dermatologic Agents (administration & dosage), Dermatologic Agents (adverse effects), Humans (MeSH), Immunocompromised Host (MeSH), Immunoglobulins (drug effects), Interleukin-17 (antagonists & inhibitors), Interleukins (antagonists & inhibitors), Interleukins (immunology), Meningococcal Vaccines (administration & dosage), Molecular Targeted Therapy (adverse effects).
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Dermatologic Agents, Meningococcal Vaccines.
- chemical , adverse effects : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Dermatologic Agents.
- chemical , antagonists & inhibitors : Interleukin-17, Interleukins.
- chemical , drug effects : Complement System Proteins, Immunoglobulins.
- chemical , immunology : Interleukins.
- chemical , therapeutic use : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized.
- adverse effects : Biological Therapy, Molecular Targeted Therapy.
- immunology : Communicable Diseases.
- therapy : Communicable Diseases.
- Clinical Trials as Topic, Communicable Disease Control, Humans, Immunocompromised Host.
Abstract
BACKGROUND
The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies.
AIMS
To review, from an Infectious Diseases perspective, the safety profile of agents targeting interleukins, immunoglobulins and complement factors and to suggest preventive recommendations.
SOURCES
Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family.
CONTENT
Patients receiving interleukin-1 (IL-1) -targeted (anakinra, canakinumab or rilonacept) or IL-5-targeted (mepolizumab) agents have a moderate risk of infection and no specific prevention strategies are recommended. The use of IL-6/IL-6 receptor-targeted agents (tocilizumab and siltuximab) is associated with a risk increase similar to that observed with anti-tumour necrosis factor-α agents. IL-12/23-targeted agents (ustekinumab) do not seem to pose a meaningful risk of infection, although screening for latent tuberculosis infection may be considered and antiviral prophylaxis should be given to hepatitis B surface antigen-positive patients. Therapy with IL-17-targeted agents (secukinumab, brodalumab and ixekizumab) may result in the development of mild-to-moderate mucocutaneous candidiasis. Pre-treatment screening for Strongyloides stercoralis and other geohelminths should be considered in patients who come from areas where these are endemic who are receiving IgE-targeted agents (omalizumab). C5-targeted agents (eculizumab) are associated with a markedly increased risk of infection due to encapsulated bacteria, particularly Neisseria spp. Meningococcal vaccination and chemoprophylaxis must be administered 2-4 weeks before initiating eculizumab. Patients with high-risk behaviours and their partners should also be screened for gonococcal infection.
IMPLICATIONS
Preventive strategies are particularly encouraged to minimize the occurrence of neisserial infection associated with eculizumab.
DOI: 10.1016/j.cmi.2018.02.002
PubMed: 29447987
Links to Exploration step
pubmed:29447987Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).</title><author><name sortKey="Winthrop, K L" sort="Winthrop, K L" uniqKey="Winthrop K" first="K L" last="Winthrop">K L Winthrop</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, USA. Electronic address: winthrop@ohsu.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Mariette, X" sort="Mariette, X" uniqKey="Mariette X" first="X" last="Mariette">X. Mariette</name><affiliation><nlm:affiliation>Department of Rheumatology, Hôpitaux Universitaire Paris-Sud, Université Paris-Sud, INSERM U1184, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Silva, J T" sort="Silva, J T" uniqKey="Silva J" first="J T" last="Silva">J T Silva</name><affiliation><nlm:affiliation>Department of Infectious Diseases, University Hospital of Badajoz, Fundación para La Formación e Investigación de Los Profesionales de La Salud (FundeSalud), Badajoz, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Benamu, E" sort="Benamu, E" uniqKey="Benamu E" first="E" last="Benamu">E. Benamu</name><affiliation><nlm:affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Calabrese, L H" sort="Calabrese, L H" uniqKey="Calabrese L" first="L H" last="Calabrese">L H Calabrese</name><affiliation><nlm:affiliation>Department of Rheumatic and Immunological Diseases, Cleveland Clinic Foundation, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Case Western University, Cleveland, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dumusc, A" sort="Dumusc, A" uniqKey="Dumusc A" first="A" last="Dumusc">A. Dumusc</name><affiliation><nlm:affiliation>Department of Rheumatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Smolen, J S" sort="Smolen, J S" uniqKey="Smolen J" first="J S" last="Smolen">J S Smolen</name><affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Aguado, J M" sort="Aguado, J M" uniqKey="Aguado J" first="J M" last="Aguado">J M Aguado</name><affiliation><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Fernandez Ruiz, M" sort="Fernandez Ruiz, M" uniqKey="Fernandez Ruiz M" first="M" last="Fernández-Ruiz">M. Fernández-Ruiz</name><affiliation><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29447987</idno><idno type="pmid">29447987</idno><idno type="doi">10.1016/j.cmi.2018.02.002</idno><idno type="wicri:Area/Main/Corpus">000943</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000943</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).</title><author><name sortKey="Winthrop, K L" sort="Winthrop, K L" uniqKey="Winthrop K" first="K L" last="Winthrop">K L Winthrop</name><affiliation><nlm:affiliation>Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, USA. Electronic address: winthrop@ohsu.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Mariette, X" sort="Mariette, X" uniqKey="Mariette X" first="X" last="Mariette">X. Mariette</name><affiliation><nlm:affiliation>Department of Rheumatology, Hôpitaux Universitaire Paris-Sud, Université Paris-Sud, INSERM U1184, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Silva, J T" sort="Silva, J T" uniqKey="Silva J" first="J T" last="Silva">J T Silva</name><affiliation><nlm:affiliation>Department of Infectious Diseases, University Hospital of Badajoz, Fundación para La Formación e Investigación de Los Profesionales de La Salud (FundeSalud), Badajoz, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Benamu, E" sort="Benamu, E" uniqKey="Benamu E" first="E" last="Benamu">E. Benamu</name><affiliation><nlm:affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Calabrese, L H" sort="Calabrese, L H" uniqKey="Calabrese L" first="L H" last="Calabrese">L H Calabrese</name><affiliation><nlm:affiliation>Department of Rheumatic and Immunological Diseases, Cleveland Clinic Foundation, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Case Western University, Cleveland, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dumusc, A" sort="Dumusc, A" uniqKey="Dumusc A" first="A" last="Dumusc">A. Dumusc</name><affiliation><nlm:affiliation>Department of Rheumatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Smolen, J S" sort="Smolen, J S" uniqKey="Smolen J" first="J S" last="Smolen">J S Smolen</name><affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Aguado, J M" sort="Aguado, J M" uniqKey="Aguado J" first="J M" last="Aguado">J M Aguado</name><affiliation><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Fernandez Ruiz, M" sort="Fernandez Ruiz, M" uniqKey="Fernandez Ruiz M" first="M" last="Fernández-Ruiz">M. Fernández-Ruiz</name><affiliation><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</title><idno type="eISSN">1469-0691</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antibodies, Monoclonal (adverse effects)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Biological Therapy (adverse effects)</term><term>Clinical Trials as Topic (MeSH)</term><term>Communicable Disease Control (MeSH)</term><term>Communicable Diseases (immunology)</term><term>Communicable Diseases (therapy)</term><term>Complement System Proteins (drug effects)</term><term>Dermatologic Agents (administration & dosage)</term><term>Dermatologic Agents (adverse effects)</term><term>Humans (MeSH)</term><term>Immunocompromised Host (MeSH)</term><term>Immunoglobulins (drug effects)</term><term>Interleukin-17 (antagonists & inhibitors)</term><term>Interleukins (antagonists & inhibitors)</term><term>Interleukins (immunology)</term><term>Meningococcal Vaccines (administration & dosage)</term><term>Molecular Targeted Therapy (adverse effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Dermatologic Agents</term><term>Meningococcal Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Dermatologic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Interleukin-17</term><term>Interleukins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Complement System Proteins</term><term>Immunoglobulins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Interleukins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Biological Therapy</term><term>Molecular Targeted Therapy</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Communicable Diseases</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Communicable Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Communicable Disease Control</term><term>Humans</term><term>Immunocompromised Host</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies.</p></div><div type="abstract" xml:lang="en"><p><b>AIMS</b></p><p>To review, from an Infectious Diseases perspective, the safety profile of agents targeting interleukins, immunoglobulins and complement factors and to suggest preventive recommendations.</p></div><div type="abstract" xml:lang="en"><p><b>SOURCES</b></p><p>Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family.</p></div><div type="abstract" xml:lang="en"><p><b>CONTENT</b></p><p>Patients receiving interleukin-1 (IL-1) -targeted (anakinra, canakinumab or rilonacept) or IL-5-targeted (mepolizumab) agents have a moderate risk of infection and no specific prevention strategies are recommended. The use of IL-6/IL-6 receptor-targeted agents (tocilizumab and siltuximab) is associated with a risk increase similar to that observed with anti-tumour necrosis factor-α agents. IL-12/23-targeted agents (ustekinumab) do not seem to pose a meaningful risk of infection, although screening for latent tuberculosis infection may be considered and antiviral prophylaxis should be given to hepatitis B surface antigen-positive patients. Therapy with IL-17-targeted agents (secukinumab, brodalumab and ixekizumab) may result in the development of mild-to-moderate mucocutaneous candidiasis. Pre-treatment screening for Strongyloides stercoralis and other geohelminths should be considered in patients who come from areas where these are endemic who are receiving IgE-targeted agents (omalizumab). C5-targeted agents (eculizumab) are associated with a markedly increased risk of infection due to encapsulated bacteria, particularly Neisseria spp. Meningococcal vaccination and chemoprophylaxis must be administered 2-4 weeks before initiating eculizumab. Patients with high-risk behaviours and their partners should also be screened for gonococcal infection.</p></div><div type="abstract" xml:lang="en"><p><b>IMPLICATIONS</b></p><p>Preventive strategies are particularly encouraged to minimize the occurrence of neisserial infection associated with eculizumab.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29447987</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0691</ISSN><JournalIssue CitedMedium="Internet"><Volume>24 Suppl 2</Volume><PubDate><Year>2018</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</Title><ISOAbbreviation>Clin Microbiol Infect</ISOAbbreviation></Journal><ArticleTitle>ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).</ArticleTitle><Pagination><MedlinePgn>S21-S40</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1198-743X(18)30150-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmi.2018.02.002</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To review, from an Infectious Diseases perspective, the safety profile of agents targeting interleukins, immunoglobulins and complement factors and to suggest preventive recommendations.</AbstractText><AbstractText Label="SOURCES" NlmCategory="METHODS">Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family.</AbstractText><AbstractText Label="CONTENT" NlmCategory="BACKGROUND">Patients receiving interleukin-1 (IL-1) -targeted (anakinra, canakinumab or rilonacept) or IL-5-targeted (mepolizumab) agents have a moderate risk of infection and no specific prevention strategies are recommended. The use of IL-6/IL-6 receptor-targeted agents (tocilizumab and siltuximab) is associated with a risk increase similar to that observed with anti-tumour necrosis factor-α agents. IL-12/23-targeted agents (ustekinumab) do not seem to pose a meaningful risk of infection, although screening for latent tuberculosis infection may be considered and antiviral prophylaxis should be given to hepatitis B surface antigen-positive patients. Therapy with IL-17-targeted agents (secukinumab, brodalumab and ixekizumab) may result in the development of mild-to-moderate mucocutaneous candidiasis. Pre-treatment screening for Strongyloides stercoralis and other geohelminths should be considered in patients who come from areas where these are endemic who are receiving IgE-targeted agents (omalizumab). C5-targeted agents (eculizumab) are associated with a markedly increased risk of infection due to encapsulated bacteria, particularly Neisseria spp. Meningococcal vaccination and chemoprophylaxis must be administered 2-4 weeks before initiating eculizumab. Patients with high-risk behaviours and their partners should also be screened for gonococcal infection.</AbstractText><AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">Preventive strategies are particularly encouraged to minimize the occurrence of neisserial infection associated with eculizumab.</AbstractText><CopyrightInformation>Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winthrop</LastName><ForeName>K L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, USA. Electronic address: winthrop@ohsu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariette</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Hôpitaux Universitaire Paris-Sud, Université Paris-Sud, INSERM U1184, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>J T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, University Hospital of Badajoz, Fundación para La Formación e Investigación de Los Profesionales de La Salud (FundeSalud), Badajoz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benamu</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>L H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Rheumatic and Immunological Diseases, Cleveland Clinic Foundation, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Case Western University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumusc</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smolen</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguado</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández-Ruiz</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), School of Medicine, Universidad Complutense, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016446">Consensus Development Conference</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Microbiol Infect</MedlineTA><NlmUniqueID>9516420</NlmUniqueID><ISSNLinking>1198-743X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003879">Dermatologic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007378">Interleukins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022401">Meningococcal Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>37CQ2C7X93</RegistryNumber><NameOfSubstance UI="C541220">canakinumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>6ZA31Y954Z</RegistryNumber><NameOfSubstance UI="C571216">brodalumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-36-7</RegistryNumber><NameOfSubstance UI="D003165">Complement System Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>A3ULP0F556</RegistryNumber><NameOfSubstance UI="C481642">eculizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>DLG4EML025</RegistryNumber><NameOfSubstance UI="C555450">secukinumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001691" MajorTopicYN="N">Biological Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003141" MajorTopicYN="N">Communicable Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003165" MajorTopicYN="N">Complement System Proteins</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003879" MajorTopicYN="N">Dermatologic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007136" MajorTopicYN="N">Immunoglobulins</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022401" MajorTopicYN="N">Meningococcal Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anakinra</Keyword><Keyword MajorTopicYN="N">Brodalumab</Keyword><Keyword MajorTopicYN="N">Canakinumab</Keyword><Keyword MajorTopicYN="N">Eculizumab</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Ixekizumab</Keyword><Keyword MajorTopicYN="N">Prevention</Keyword><Keyword MajorTopicYN="N">Rilonacept</Keyword><Keyword MajorTopicYN="N">Secukinumab</Keyword><Keyword MajorTopicYN="N">Tocilizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>01</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>02</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29447987</ArticleId><ArticleId IdType="pii">S1198-743X(18)30150-2</ArticleId><ArticleId IdType="doi">10.1016/j.cmi.2018.02.002</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000943 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000943 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= BiopestPeptidV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:29447987
|texte= ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:29447987" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a BiopestPeptidV1
| This area was generated with Dilib version V0.6.38. |  |